Ebolavirus glycoprotein base region quaternary epitope (EBOV GP base epitope)

The Ebolavirus glycoprotein (GP) base region quaternary epitope is a highly conserved structural domain located at the interface of the GP1 and GP2 subunits, situated near the viral membrane [1][3]. This epitope is characterized by its quaternary nature, requiring the specific assembly of the GP trimer to be recognized by the immune system [2][5]. It plays a fundamental role in the viral life cycle by facilitating the fusion of the viral envelope with the host endosomal membrane, a process mediated by the GP2 subunit following proteolytic cleavage of GP1 by host cathepsins [1][2]. Because the base region is less prone to mutational variation compared to the mucin-like domain or glycan cap, it is a primary target for the development of broadly neutralizing antibodies (bnAbs) that can provide protection against multiple Ebolavirus species [3][5]. Therapeutic antibodies targeting this site, such as Maftivimab and Atoltivimab (components of the FDA-approved Inmazeb), function primarily by sterically hindering the conformational changes required for membrane fusion or by recruiting immune effector cells through Fc-mediated pathways [4][5]. Targeting this site is a key strategy in developing pan-ebolavirus countermeasures to treat and prevent Ebola virus disease [1][3]. References: [1] Wec, A. Z., et al. (2017). Science. [2] Bornholdt, Z. A., et al. (2016). Cell. [3] King, L. B., et al. (2019). Journal of Virology. [4] FDA. (2020). Inmazeb Prescribing Information. [5] West, B. R., et al. (2018). Nature Communications.

Other names

GP base epitopeGP1/GP2 interface epitopeQuaternary base epitopeEbolavirus GP base

Inhibition of viral-host membrane fusion and neutralization of viral entry by blocking GP2 conformational changes and inducing Fc-mediated effector functions.